Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia

Prenatal Diagnosis

Volumn 30, Issue 3, 2010, Pages 191-197

  Akolekar, Ranjit ^a   De Cruz, Jader ^a,b   Foidart, Jean Michel ^c   Munaut, Carine ^c   Nicolaides, Kypros H ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

First trimester; Placental growth factor; Preeclampsia; Soluble fms like tyrosine kinase 1; Uterine artery doppler; Vascular endothelial growth factor

Indexed keywords

FMS LIKE TYROSINE KINASE 1; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANAMNESIS; ARTICLE; BIRTH WEIGHT; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GESTATION PERIOD; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARITY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; QUESTIONNAIRE; RACE DIFFERENCE; SMALL FOR DATE INFANT; UTERINE ARTERY;

ADULT; BLOOD FLOW VELOCITY; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PROSPECTIVE STUDIES; UTERINE ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77349114204     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2433     Document Type: Article

References (54)

1. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. 2008. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 32: 732-739.
2. Banks RE, Forbes MA, Searles J, et al. 1998. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod 4: 377-386.
3. Baumann MU, Bersinger NA, Mohaupt MG, et al. 2008. Firsttrimester serum levels of soluble endoglin and soluble fmslike tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 199: 266.e1-266.e6.
4. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. 2001. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 20: IX-XIV.
5. Buhimschi CS, Magloire L, Funai E, et al. 2006. Fractional excretion of angiogenic factors in women with severe preeclampsia. Obstet Gynecol 107: 1103-1113.
6. Clark DE, Smith SK, He Y, et al. 1998. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 59: 1540-1548.
7. De Vivo A, Baviera G, Giordano D, et al. 2008. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 87: 837-842.
8. Erez O, Romero R, Espinoza J, et al. 2008. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-forgestational age. J Matern Fetal Neonatal Med 21: 279-287.
9. Gardosi J, Francis A. 2007. Customised Centile Calculator-GROWCentile v 6.2.2. Gestation Network, www.gestation.net.
10. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. 1999. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 13: 537-545.
11. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. 2008. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin, and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 31: 618-624.
12. Karumanchi SA, Bdolah Y. 2004. Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology 145: 4835-4837.
13. Kaufmann P, Mayhew TM, Charnock-Jones DS. 2004. Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta 25: 114-126.
14. Kendall RL, Thomas KA. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709.
15. Khong TY, De Wolf F, Robertson WB, Brosens I. 1986. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 93: 1049-1059.
16. Kim SY, Ryu HM, Yang JH, et al. 2007. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 22: 873-877.
17. Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. 2009. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 29: 464-470.
18. Lam C, Lim KH, Karumanchi SA. 2005. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46: 1077-1085.
19. Lee ES, Oh MJ, Jung JW, et al. 2007. The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia. J Korean Med Sci 22: 94-98.
20. Levine RJ, Karumanchi SA. 2005. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 48: 372-386.
21. Levine RJ, Maynard SE, Qian C, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683.
22. Lewis G (ed). 2004. Confidential Enquiries into Maternal and Child Health. Why Mothers Die 2000-2002: The Sixth Report of United Kingdom Confidential Enquiries Into Maternal Deaths in the United Kingdom. RCOG Press: London.
23. Lim JH, Kim SY, Park SY, et al. 2008. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 111: 1403-1409.
24. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. 2000. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 183: 1554-1557.
25. Lockwood CJ, Toti P, Arcuri F, et al. 2007. Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. Am J Pathol 170: 1398-1405.
26. Lyall F, Greer IA, Boswell F, Fleming R. 1997. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 104: 223-228.
27. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. 2007. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 92: 2672-2679.
28. Maynard SE, Min JY, Merchan J, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
29. Maynard S, Epstein FH, Karumanchi SA. 2008. Preeclampsia and angiogenic imbalance. Annu Rev Med 59: 61-78.
30. Muy-Rivera M, Vadachkoria S, Woelk GB, et al. 2005. Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women. Physiol Res 54: 611-622.
31. Nagamatsu T, Fujii T, Kusumi M, et al. 2004. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145: 4838-4845.
32. Park CW, Park JS, Shim SS, et al. 2005. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 193: 984-989.
33. Pijnenborg R, Anthony J, Davey DA, et al. 1991. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 98: 648-655.
34. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. 2007. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 30: 742-749.
35. Polliotti BM, Fry AG, Saller DN, et al. 2003. Second trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 101: 1266-1274.
36. Poon LCY, Kametas NA, Chelemen T, Leal A, Nicolaides KH. 2009a. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens [Epub ahead of print] DOI: 10.1038/jhh.2009.45.
37. Poon LCY, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH. 2009b. Hypertensive disorders in pregnancy: Screening by uterine artery Doppler at 11-13 weeks. Ultrasound Obstet Gynecol 34: 142-148.
38. Rana S, Karumanchi SA, Levine RJ, et al. 2007. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50: 137-142.
39. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S. 2009. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PloS One 4: e4453.
40. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. 1999. Selective deficit of angiogenic growth factors characterizes pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 106: 1019-1022.
41. Romero R, Nien JK, Espinoza J, et al. 2008. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21: 9-23.
42. Salahuddin S, Lee Y, Vadnais M, et al. 2007. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 197: 28.e1-28.e6.
43. Shibata E, Rajakumar A, Powers RW, et al. 2005. Soluble fmslike tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 90: 4895-4903.
44. Smith GC, Crossley JA, Aitken DA, et al. 2007. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 109: 1316-1324.
45. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352: 343-346.
46. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. 2005. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 122: 33-39.
47. Stepan H, Kr̈amer T, Faber R. 2007. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 92: 2831-2834.
48. Thadhani R, Mutter WP, Wolf M, et al. 2004. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89: 770-775.
49. Tsatsaris V, Goffin F, Munaut C, et al. 2003. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88: 5555-5563.
50. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. 2005. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 193: 429-436.
51. Vatten LJ, Eskild A, Nilsen TI, et al. 2007. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 196: 239.e1-239.e6.
52. Woolcock J, Hennessy A, Xu B, et al. 2008. Soluble Flt-1 as a diagnostic marker of pre-eclampsia. Aust N Z J Obstet Gynaecol 48: 64-70.
53. World Health Organization. 2005. Make Every Mother and Child Count. World Health Report, 2005. World Health Organization: Geneva, Switzerland.
54. Zhou Y, McMaster M, Woo K, et al. 2002. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160: 1405-23.